<DOC>
	<DOCNO>NCT00002115</DOCNO>
	<brief_summary>To study safety , tolerance , pharmacokinetics , anti-HIV effect PMEA ( adefovir ) administer daily intravenous ( IV ) and/or subcutaneous ( SC ) injection patient advance HIV disease .</brief_summary>
	<brief_title>A Phase I/II Study Safety , Tolerance , Pharmacokinetics 9- ( 2-Phosphonylmethoxyethyl ) Adenine ( PMEA ; Adefovir ) Patients With Advanced HIV Disease .</brief_title>
	<detailed_description>Patients receive single IV SC dose PMEA daily 4 week . A maximum tolerated dose define regimen .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Other antiretroviral therapy IF stable dose least 4 week prior study entry . Prophylactic therapy aerosolize pentamidine , oral trimethoprim/sulfamethoxazole ( Bactrim , Septra ) dapsone , fluconazole ketoconazole IF stable prophylactic regimen least 4 week prior study entry . Patients must : HIV seropositivity . Elevated p24 antigen ( &gt; 40 pg/ml ) . Mean CD4 count &lt; = 100 cells/mm3 . Life expectancy least 3 month . Prior Medication : Allowed : Other prior antiretroviral therapy . Prophylactic therapy aerosolize pentamidine , oral trimethoprim/sulfamethoxazole ( Bactrim , Septra ) dapsone , fluconazole ketoconazole . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Inadequate venous access . Active serious infection ( HIV infection ) require parenteral antibiotic therapy . Clinically significant cardiac disease , include symptom ischemia , congestive heart failure , arrhythmia . Psychiatric disturbance illness may affect compliance . Malignancy Kaposi 's sarcoma . Concurrent Medication : Excluded : Investigational agent stavudine ( d4T ) . Interferonalpha . Ganciclovir . Foscarnet . Diuretics . Amphotericin B. Aminoglycoside antibiotic . Other nephrotoxic agent . Acyclovir dose &gt; = 2 g/day . Prior Medication : Excluded within 2 week prior study entry : Investigational agent stavudine ( d4T ) . Interferonalpha . Ganciclovir . Foscarnet . Diuretics . Amphotericin B. Aminoglycoside antibiotic . Other nephrotoxic agent . Excluded within 4 week prior study entry : Systemic therapy Kaposi 's sarcoma . Substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 1995</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Adenine</keyword>
</DOC>